RIPK1 and Decreased liver function: By doing so, patient populations most likely to benefit can be identified while avoiding severe toxicity in susceptible individuals (e.g., those with liver dysfunction), thus increasing the success rate of clinical trials and uncovering the true clinical value of RIPK1 targeting.